In our analysis, the heterozygous group had a higher incidence of severe neutropenia and febrile neutropenia than patients with UGT1A1 *1/*1, requiring a further reduction in nal-IRI, even though many of them had received a reduced starting dose of nal-IRI. The gene discussed is UGT1A1; the disease is neutropenia.